Singapore's S*BIO Shutters Discovery Operations To Focus On Finding Partners For Lead JAK2 Inhibitor, Interim CEO Says
This article was originally published in PharmAsia News
Executive Summary
Dispelling rumors that S*BIO is on the sales block, interim CEO Tamar Howson told PharmAsia News that the company is refocusing its efforts from being a discovery-oriented biotech company to commercializing its late-stage products